191 related articles for article (PubMed ID: 26897933)
1. Mystery Story about Erythropoietin (Epo) and Erythropoietin Receptor (EpoR) are Disguised?
Cubranić A; Redzovic A; Dobrila-Dintinjana R; Vukelić J; Dintinjana M
Hepatogastroenterology; 2015 May; 62(139):585-9. PubMed ID: 26897933
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression.
Acs G; Zhang PJ; McGrath CM; Acs P; McBroom J; Mohyeldin A; Liu S; Lu H; Verma A
Am J Pathol; 2003 Jun; 162(6):1789-806. PubMed ID: 12759237
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin and erythropoietin receptor expression in vestibular schwannoma: potential role in tumor progression.
Diensthuber M; Ilner T; Rodt T; Samii M; Brandis A; Lenarz T; Stöver T
Otol Neurotol; 2007 Jun; 28(4):559-65. PubMed ID: 17429338
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma.
Ribatti D; Marzullo A; Gentile A; Longo V; Nico B; Vacca A; Dammacco F
Histopathology; 2007 Apr; 50(5):591-6. PubMed ID: 17394495
[TBL] [Abstract][Full Text] [Related]
5. The relationships between hypoxia-dependent markers: HIF-1alpha, EPO and EPOR in colorectal cancer.
Baltaziak M; Wincewicz A; Kanczuga-Koda L; Lotowska JM; Koda M; Sulkowska U; Baltaziak M; Podbielski M; Sobaniec-Lotowska ME; Sulkowski S
Folia Histochem Cytobiol; 2013; 51(4):320-5. PubMed ID: 24497137
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma.
Ribatti D; Poliani PL; Longo V; Mangieri D; Nico B; Vacca A
Histopathology; 2007 Apr; 50(5):636-41. PubMed ID: 17394500
[TBL] [Abstract][Full Text] [Related]
7. STAT3, HIF-1alpha, EPO and EPOR - signaling proteins in human primary ductal breast cancers.
Wincewicz A; Sulkowska M; Koda M; Leśniewicz T; Kanczuga-Koda L; Sulkowski S
Folia Histochem Cytobiol; 2007; 45(2):81-6. PubMed ID: 17597020
[TBL] [Abstract][Full Text] [Related]
8. STAT3 and hypoxia induced proteins--HIF-1alpha, EPO and EPOR in relation with Bax and Bcl-xL in nodal metastases of ductal breast cancers.
Wincewicz A; Koda M; Sulkowska M; Kanczuga-Koda L; Wincewicz D; Sulkowski S
Folia Histochem Cytobiol; 2009 Jan; 47(3):425-30. PubMed ID: 20164027
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts.
Tankiewicz-Kwedlo A; Hermanowicz J; Surażynski A; Rożkiewicz D; Pryczynicz A; Domaniewski T; Pawlak K; Kemona A; Pawlak D
Mol Cell Biochem; 2016 Oct; 421(1-2):1-18. PubMed ID: 27543111
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of erythropoietin expression in human endometrial carcinoma.
Acs G; Xu X; Chu C; Acs P; Verma A
Cancer; 2004 Jun; 100(11):2376-86. PubMed ID: 15160341
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin-responsive sites in normal and malignant human lung tissues.
Yasuda Y; Hara S; Hirohata T; Koike E; Yamasaki H; Okumoto K; Hoshiai H
Anat Sci Int; 2010 Dec; 85(4):204-13. PubMed ID: 20397063
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin and its receptor in breast cancer: putting together the pieces of the puzzle.
Mannello F; Tonti GA
Oncologist; 2008 Jul; 13(7):761-8. PubMed ID: 18596367
[TBL] [Abstract][Full Text] [Related]
13. Targeted near-infrared imaging of the erythropoietin receptor in human lung cancer xenografts.
Doleschel D; Mundigl O; Wessner A; Gremse F; Bachmann J; Rodriguez A; Klingmüller U; Jarsch M; Kiessling F; Lederle W
J Nucl Med; 2012 Feb; 53(2):304-11. PubMed ID: 22228796
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin and the hypoxic brain.
Marti HH
J Exp Biol; 2004 Aug; 207(Pt 18):3233-42. PubMed ID: 15299044
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin and co.: intrinsic structure and functional disorder.
Uversky VN; Redwan EM
Mol Biosyst; 2016 Dec; 13(1):56-72. PubMed ID: 27833947
[TBL] [Abstract][Full Text] [Related]
16. Emergence of the erythropoietin/erythropoietin receptor system as a novel cardiovascular therapeutic target.
Satoh K; Fukumoto Y; Nakano M; Kagaya Y; Shimokawa H
J Cardiovasc Pharmacol; 2011 Dec; 58(6):570-4. PubMed ID: 21934628
[TBL] [Abstract][Full Text] [Related]
17. Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients.
Lamanuzzi A; Saltarella I; Ferrucci A; Ria R; Ruggieri S; Racanelli V; Rao L; Annese T; Nico B; Vacca A; Ribatti D
Oncotarget; 2016 Mar; 7(12):14510-21. PubMed ID: 26919105
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin is a hypoxia inducible factor-induced protective molecule in experimental autoimmune neuritis.
Luo B; Jiang M; Yang X; Zhang Z; Xiong J; Schluesener HJ; Zhang Z; Wu Y
Biochim Biophys Acta; 2013 Aug; 1832(8):1260-70. PubMed ID: 23603807
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of erythropoietin and its receptor expression in the rat carotid body during chronic and intermittent hypoxia.
Lam SY; Tipoe GL; Fung ML
Adv Exp Med Biol; 2009; 648():207-14. PubMed ID: 19536483
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of erythropoietin and erythropoietin receptor in gastric adenocarcinoma.
Wang L; Li HG; Xia ZS; Wen JM; Lv J
World J Gastroenterol; 2011 Sep; 17(34):3933-40. PubMed ID: 22025882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
